BioDFence® G3 For Full Nerve-Sparing Robotic-Assisted Radical Prostatectomy

Trial details

Who runs it

AdventHealth

Trial code

NCT05363644

Record updated

2023. június 29.

Original description

The purpose of this study is to assess functional outcomes post operatively after the use of BioDFence® G3 during robotic radical prostatectomy.Read full original descriptionShow less

Treatment Protocol With BioDFence® G3 For Full Nerve-Sparing Robotic-Assisted Radical Prostatectomy: A Prospective Open Label Single-Center Study

The purpose of this study is to assess functional outcomes post operatively after the use of BioDFence® G3 during robotic radical prostatectomy.

Inclusion: Male subjects between the ages 40-70; Primary diagnosis of prostate cancer requiring surgical intervention; Have a willingness to comply with follow-up requirements; Have ability to provide full written consent; Primary diagnosis of untreated with clinically localized prostate cancer with Gleason score of 6, or 7; Planned elective radical prostatectomy with bilateral full nerve sparing technique; Patients who currently have a pre-operative SHIM > 19.

Exclusion: Is unable to comply with penile rehabilitation, including oral 5-phosphodiesterase inhibitor; Patients with a history of more than two weeks treatment with immuno-suppressants (including systemic corticosteroids), cytotoxic chemotherapy within one month prior to initial screening, or who receive such medications during the screening period, or who are anticipated to require such medications during the course of the study; Has had prior hormonal therapy such as Lupron or oral anti-androgens; Has signs or symptoms of any other disease which could result in allograft failure or has experienced graft failure in the past; Has any condition(s), which seriously compromises the subject's ability to participate in this study or has a known history of poor adherence with medical treatment; Has comorbid conditions that can be confused with or can exacerbate the condition of erectile dysfunction, including:; Diabetes Type I or Type II; Advanced atherosclerotic vascular disease; Has a documented medical history of drug or alcohol abuse within last 12 months; Has autoimmune disease or a known history of having Acquired Immunodeficiency Syndrome (AIDS) or HIV; Is unable to sign or understand informed consent; Known sensitivity to glutaraldehyde or ethanol; Living outside of United States; Partial nerve sparing technique used during Radical Prostatectomy.

ClinicalTrials.gov NCT05363644